Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz Inc.

www.us.sandoz.com

Latest From Sandoz Inc.

Who’s Hired? ANI Pharma Strengthens Leadership With Three New Executives

ANI pharma strengthens leadership team by adding three new executives to accelerate future growth. While Coherus and Xbrane appoint new chief financial officers, Lupin and Beximco hire new independent directors. Sandoz is certified “Global Top Employer 2021” yet again by Top Employers Institute.

Leadership Strategy

Sandoz Takes Enbrel Fight To The US Supreme Court

Sandoz had hinted that further legal action was viable as it looks to introduce biosimilar competition to Amgen’s Enbrel blockbuster in the US. The Novartis subsidiary has now taken its fight to the very highest court.

Biosimilars Intellectual Property

Europe Puts Its API Dependence On Asia Under The Microscope

The high concentration of API manufacturers in India and China posing a risk to the European supply chain became the highlight of the discussion among panellists at a recent Medicines for Europe webinar, as possible solutions to reduce the risk of shortages were pitched.

Europe Manufacturing

BsUFA Suggestions From Sponsors Sound Easy, But Changes May Be Difficult For US FDA

Biosimilar sponsors want meeting and assessment best practices implemented across divisions, but the FDA says that may be difficult and time-consuming.

Biosimilars Review Pathway
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
UsernamePublicRestriction

Register